TTS Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$79,249	3
2024	Research	$58,932	3
2023	Research	$5,529	4
2022	Research	$60,256	6
2021	Research	$428,781	11
2020	Research	$198,217	15
2019	Research	$359,960	77

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $779,969 18 payments
Teva Pharmaceuticals USA, Inc. $153,198 21 payments
Amgen Inc. $135,512 3 payments
Merck Sharp & Dohme Corporation $108,901 9 payments
ALK-Abello, Inc $8,743 65 payments
Cipla USA Inc. $2,600 2 payments
Chiesi USA, Inc. $2,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of Csj117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. $526,998 5 payments
A 52 Week Multicenter Randomized Double Blind Double Dummy Parallel Group Placebo Controlled Study of Fevipiprant Once Daily Plus Standard of Care Soc for Reduction of Systemic Corticosteroids Oral and Parenteral Use in Patients With Severe Asthma $155,376 2 payments
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $153,198 21 payments
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma $76,649 1 payment
A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed Ambrosia artemisiifolia Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma $66,749 4 payments
STARLIGHT P2 LCM Asthma $58,862 2 payments
A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of Qaw039 When Added to Standard-Of-Care Asthma Therapy in Patients With Uncontrolled Asthma $36,037 2 payments
A 52 Week Multicenter Randomized Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of Qaw039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Eosinophilic Asthma $34,012 3 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 Laboratory-confirmed SARS-CoV-2 Infection With Symptoms in Adults Residing With a Person With COVID-19 $31,652 4 payments
A Multi-Center, Proof-Of-Mechanism Study of Multiple, Oral Doses of Fevipiprant (Qaw039) in COPD Patients With Sputum Eosinophilia $13,571 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.